Simtra BioPharma Solutions expands U.S. manufacturing capacity for injectable medicines
Simtra positioned to become the first CDMO to offer commercial-scale drug product manufacturing of antibody-drug conjugates in the United States
Advertisement
Simtra BioPharma Solutions announced the purchase from Cook Group of a 65-acre property (301 N. Curry Pike) with more than 300,000 square feet of available space for expansion under-roof near its existing manufacturing facility in Bloomington, Indiana.
Leveraging Simtra's experience and expertise in manufacturing next generation oncology treatments, including antibody-drug conjugates (ADCs), at its site in Halle/Westfalen, Germany, the addition of this site provides Simtra significant flexibility to rapidly expand its manufacturing footprint in the United States to respond to growing capacity demands from both new and existing customers.
"This purchase gives us the foundation to grow with purpose, building the advanced injectable capacity our customers need while strengthening our presence in North America," said Franco Negron, Chief Executive Officer, Simtra BioPharma Solutions. "It reflects our long-term commitment to delivering vital injectable products and helping our customers navigate complex global supply chains."
Simtra is evaluating a project to design and install manufacturing lines at the site, including the Company's first U.S.-based commercial-scale capacity for oncology-focused injectable drug products. The facility would run isolator-based vial and prefilled syringe filling lines. Simtra's model allows for "build-to-suit" solutions that meet the unique needs of individual customers and their products.
This purchase complements other previously announced investments in the Company's growth, including the $250 million construction project currently underway at Simtra's existing Bloomington manufacturing site, and the recently completed $100+ million new production building and $14 million conjugation and purification suite being built in Halle/Westfalen, Germany. Together, the U.S. and German investments reflect a balanced, global approach to growth, ensuring Simtra can support customers across both continents.
Other news from the department manufacturing
Most read news
More news from our other portals
Last viewed contents
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
ChatGPT grows insect-toxic genetically engineered plant - Blind spot in the EU draft law on genetic engineering
Commission launches new strategy to make Europe a global leader in life sciences by 2030
CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech - BioNTech’s acquisition of CureVac will be implemented as planned
Ibidi Awarded With the German bAV Prize 2023
Using AI as an exam tutor - Artificial intelligence is set to help human examinees study more effectively
EXIST start-up grant for virtual reality laboratory training - "Wet-Lab-VR": Virtual reality technology revolutionises training for molecular biology laboratories
Sustainable Plastics from Plants - Innovative interdisciplinary education model
How immune cells become accomplices of tumors - Langener Wissenschaftspreis awarded to DKFZ researcher Daniel Kirschenbaum
How the biological clock ticks in the female reproductive tract - Breakthrough of the Year Award 2025 for Ângela Gonçalves
Boehringer Ingelheim announces change in the company management - Harsha Deshmukh has been appointed as a member of the Executive Board with responsibility for IT and Global Business Services with effect from February 1, 2026
